Organ preservation for rectal cancer: long-course chemoradiation vs short-course radiation therapy

Paul Bernard Romesser, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of an investigation into long-course chemoradiation versus short-course radiation therapy for organ preservation with total neoadjuvant therapy for rectal cancer. Both long-course chemoradiation versus short-course radiation therapy achieved a complete clinical response of 46%, however, there was a higher rate of organ preservation at 2 years for patients who had long-course chemoradiation compared to short-course radiation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.